March 20, 2020 07:40 AM EDTUpdated 08:48 AM
Financing
China

In­no­Care IPO over­sub­scribed 300x as Hong Kong in­vestors turned to biotech amid runoff

Jason Mast

Editor

For­get the glob­al stock melt­down. Or at least Chi­nese biotech In­no­Care did, forg­ing ahead with a more than $250-mil­lion IPO in Hong Kong de­spite …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times